TAPVR is a congenital heart disease in which the pulmonary veins drain into the right side of the heart, returning all the venous blood into the systemic venous system, and thereby creating a large left-to-right shunt. Almost always, this condition is associated with an atrial septal defect. The consequence of such an anomaly is the failure of separation of oxygenated and deoxygenated blood, and diminished oxygen content of the arterial blood, leading to cyanosis. In addition, an increased volume load is placed on the right ventricle. Three different forms of the disorder have been recognized based on the drainage of the venous blood into the right atrium via either the superior vena cava (Supracardiac form), the coronary sinus (Cardiac form), or the hepatic veins and inferior vena cava (Infracardiac form). The condition takes a severe form in patients who have an obstructed pulmonary venous return. Such patients appear severely cyanotic immediately after birth and show the signs and symptoms characteristic of this condition, including cyanosis, respiratory distress, and heart murmur. Individuals devoid of the obstruction in the pulmonary venous return may remain largely asymptomatic.
TAPVD is suspected with a heart murmur. ECG may show evidence of right atrial and left ventricular enlargement, while X-rays may show heart enlargement and pulmonary edema. Oxygen saturation will also show a typically low value. Surgical repair is the only form of treatment and should be performed in early infancy. Surgery involves connecting the pulmonary veins to the left atrium and closing the atrial septal defect. Regular lifelong follow-up is required after surgery. Some recent work has suggested that ligation of the vertical vein is not a mandatory component of successful surgical correction of this anomaly. In selected cases, non-ligation of the vertical vein may be an advantage and the unligated vein could be expected to close off.
In families where TAPVD affects multiple members, it is inherited in an autosomal dominant manner. The condition has been mapped to the 4q12 chromosomal locus. Interestingly, a vascular endothelial growth factor receptor with a prominent role in vasculogenesis maps to the same locus and has been implicated as the gene responsible for the condition.